ReviewFrontiers in immunology2021
Autoantibodies in the Diagnosis, Monitoring, and Treatment of Membranous Nephropathy.
Review in Frontiers in immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 1 synthesis or guideline pooled it, 48 citations in OpenAlex.
- Recent Advances in Clinical Diagnosis and Pharmacotherapy Options of Membranous Nephropathy.Frontiers in pharmacology · 2022Pooled it
- A preliminary nomogram model for predicting relapse of patients with primary membranous nephropathy.Renal failure · 2023Trial
- Mechanisms of Podocyte Injury in Kidney Allografts.Kidney360 · 2026Review
- Delayed but durable remission to rituximab in PLA2R-associated membranous nephropathy despite B-cell reconstitution: a case report.BMC nephrology · 2026Article
- Obinutuzumab Versus Rituximab for the Treatment of Primary Membranous Nephropathy: A Systematic Review and Meta-Analysis.Life (Basel, Switzerland) · 2026Review
- Characteristics of the gut mycobiome in patients with membranous nephropathy.Scientific reports · 2026Article
- NELL-1: role and mechanisms in disease pathogenesis and development.Frontiers in cell and developmental biology · 2026Review
- Immunotherapy of membranous nephropathy: strategic evolution from CD20 monoclonal antibodies to future vaccines.Frontiers in immunology · 2026Review
- INPP5D/SHIP1-mediated immunometabolic remodeling of renal monocytes in idiopathic membranous nephropathy.Frontiers in immunology · 2026Article
- Narrative review on decoding the crosstalk between lipid homeostasis and immune pathways in membranous nephropathy.BMC nephrology · 2025Review
- Article
- Immune Checkpoint Signatures in Minimal Change Disease and Membranous Nephropathy: Divergent Pathways of a Shared Imbalance.International journal of molecular sciences · 2025Article
- Spontaneous remission in primary membranous nephropathy: mechanisms, predictive factors, and implications for personalized management.Frontiers in immunology · 2025Review
- Case Report: A case of membranous nephropathy associated with primary Sjögren's syndrome treated with telitacicept.Frontiers in immunology · 2025Article
- Low-dose cyclophosphamide combined with chinese herbal medicine Shuli Fenxiao formula for the treatment of intermediate-to-high risk primary membranous nephropathy.Frontiers in immunology · 2025Article
- Case Report: Membranous nephropathy associated with mantle cell lymphoma: a rare case.Frontiers in medicine · 2025Article
- Comparations of efficacy and safety of rituximab, calcineurin inhibitors and cyclophosphamide in primary membranous nephropathy: a single-center retrospective analysis.BMC nephrology · 2024Article
- Clinicopathological characteristics and outcomes of PLA2R related idiopathic membranous nephropathy in patients with seronegative PLA2R antibodies.Renal failure · 2024Article
- THSD7A as a Promising Biomarker for Membranous Nephrosis.Molecular biotechnology · 2024Review
- Membranous nephropathy: pathogenesis and treatments.MedComm · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The discovery of anti-podocyte antibodies in primary membranous nephropathy (MN) has revolutionized our approach toward the diagnosis and treatment of this disease. Evaluation of serum levels of anti-podocyte antibodies paved the way for non-invasive diagnosis and helped distinguish between primary and secondary MN although the relationship between anti-podocyte antibodies and cancer remains to be elucidated. Serum levels of anti-PLA2R antibodies directed against the major podocyte autoantigen are related to MN activity and the decrease in serum levels of anti-PLA2R antibodies in response to treatment (immunologic remission) also serves as an early indicator of the later putative proteinuric remission, enabling personalization of the treatment. The serum levels of anti-podocyte antibodies also enable the prediction of renal outcomes in terms of both remission and the risk of progression to end-stage renal disease. The positivity of anti-PLA2R antibodies before renal transplantation is associated with the risk of recurrence of MN. It remains to be established if all these relations observed in patients with anti-PLA2R antibodies are also valid for expanding spectrum of antibodies directed against recently discovered minor antigens (e.g., THSD7A, NELL-1, semaphorin 3B).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.